Second CRL given to Acacia after ‘continuing deficiencies’

By Maggie Lynch

- Last updated on GMT

(Image: Getty/david hagerman)
(Image: Getty/david hagerman)

Related tags Crl Acacia Fda NDA API Gmp Manufacturing

Acacia Pharma receives a second CRL from the US FDA regarding its NDA, after GMP deficiencies during API production were revealed again.

The US Food and Drug Administration (FDA) sent the company a complete response letter (CRL) after ‘continuing deficiencies’ were found at the unnamed contract manufacturer of the active pharmaceutical ingredient (API) of its drug candidate, Barhemsys (amisulpride injection).

Julian Gilbert, CEO of Acacia, said in a statement, that the company is ‘extremely disappointed’ that the amisulpride manufacturer in its application has still not been able to meet the FDA’s required standards.

Barhemsys is a treatment for post-operative nausea and vomiting. Acacia is focused on the development of anti-nausea and vomiting treatments for surgical and cancer patients. It has a further two product candidates that are based on the same API as Barhemsys in its pipeline.

According to Acacia, the FDA found no concerns with the clinical and non-clinical data submitted in the new drug application (NDA) and no further studies nor data analyses will be required for approval.

“As there were no other issues raised with our application, we remain confident that Barhemsys is approvable. We are on track to complete the qualification of an alternative supplier of amisulpride and plan to engage with the FDA as soon as possible to determine the most rapid route to obtaining approval for Barhemsys,”​ Gilbert added.

After its first CRL​, Acacia remained committed to its API manufacturer stating that that contractor had been working collaboratively with the company to resolve the issue.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us